Waters Shares Surge as Acquisition Integration Fuels Strong First-Quarter Beat

Waters Corporation reports Q1 2026 revenue of $1.267B, adjusted EPS up 20% to $2.70, driven by strong organic growth and successful acquisition integration.

Waters Corporation delivered a standout performance in the first quarter of 2026, with revenue and earnings surpassing both internal forecasts and analyst expectations. The positive momentum sent shares sharply higher, as investors cheered the successful absorption of recently acquired businesses.

Revenue for the three-month period reached $1.267 billion, exceeding the top end of the company’s own guidance range by $56 million. The newly integrated Biosciences and Diagnostic Solutions divisions, acquired in February, contributed $520 million to the top line. On an organic basis, revenues climbed 11 percent on a currency-adjusted basis, underscoring strength in Waters’ core operations.

Adjusted earnings per share rose 20 percent year over year to $2.70, comfortably ahead of consensus estimates. However, on a GAAP basis, the company reported a loss of $0.87 per share, which management attributed to one-time integration costs and purchase price allocation expenses tied to the acquisitions.

Chief Executive Udit Batra highlighted the benefits of the company’s new four-division structure, noting that both Biosciences and Advanced Diagnostics are expanding at a faster clip than before the deal closed. The tighter alignment across units is expected to accelerate future product launches.

The stock jumped as much as 13 percent in early trading, reaching €293.00 in European markets before settling at €278.40, a gain of 7.74 percent on the day. Despite the rally, the shares remain roughly 10 percent lower year to date. The Relative Strength Index now stands near 70, a level that suggests the stock is approaching technically overbought territory.

Looking ahead, management raised its full-year 2026 adjusted earnings guidance to a range of $14.40 to $14.60 per share. For the second quarter, the company forecast adjusted EPS of up to $3.05 and revenue of as much as $1.631 billion.

Beyond the financials, Waters is advancing its product pipeline. The omniDAWN detector for laboratory applications is slated for a summer launch, and a recently developed HPV self-test has secured FDA approval.

Analysts remain broadly positive on the stock, with a consensus rating of moderate buy and an average price target of $387.53. The successful integration of the latest acquisitions, combined with robust organic growth, has positioned Waters to deliver on its upgraded targets for the year.